Last reviewed · How we verify
SMP-100
At a glance
| Generic name | SMP-100 |
|---|---|
| Also known as | ALB-137391(a), CSTI-300, SMP-100 oral solution, SMP-100 tablet |
| Sponsor | Chengdu SciMount Pharmatech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability (PHASE1)
- A Phase 1 Study of SMP-100 in Normal Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SMP-100 CI brief — competitive landscape report
- SMP-100 updates RSS · CI watch RSS
- Chengdu SciMount Pharmatech Co., Ltd. portfolio CI